Skip to content

Inspection Record

Qilu Pharmaceutical (Hainan) Co., Ltd. — FDA 483 Findings

US FDAInspected 2025-08-22Published 2026-10-26 3 findingsProcess validationLaboratory and QC controlsEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics ofdrug products.

2Laboratory and QC controls

The use of laboratory instruments not meeting established specifications was observed.

3Equipment and facility

Equipment used in the manufacturing of drug products is not of adequate size.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Qilu Pharmaceutical (Hainan) Co., Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.